Latest Breaking News On - Leap therapeutics - Page 1 : comparemela.com

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiSouth koreaJin wangGenentechf hoffmannAsher biotherapeuticsDaiichi sankyoChipscreen biosciencesBristol myers squibbAshfield medcommsMerck biopharmMerck seronoSamsung bioepisLyell immunopharmaCalithera biosciencesEli lilly

Leap Therapeutics Reports First Quarter 2024 Financial Results

Leap Therapeutics Reports First Quarter 2024 Financial Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMatthew deyoungDouglase onsiPrnewswire leap therapeutics incAmerican society of clinical oncologyGilead sciences incDrug administrationLeap therapeutics incGilead sciencesSamsara biocapitalLaurion capital managementRock springsChief executive officerCommon stockDefiance study

LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024

LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Leap therapeuticsPlace earnings

Leap Therapeutics (NASDAQ:LPTX) vs Dyne Therapeutics (NASDAQ:DYN) Financial Survey

Leap Therapeutics (NASDAQ:LPTX – Get Free Report) and Dyne Therapeutics (NASDAQ:DYN – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings. Volatility and Risk Leap Therapeutics has a beta […]

New zealandUnited statesUnited kingdomBeigene ltdLeap therapeutics incDyne therapeutics incHealthcare pharmaceuticals incLeap therapeuticsGet free reportDyne therapeuticsDyne therapeuticGiven leap therapeuticHealthcare pharmaceuticalsLeap therapeutics dailyNasdaq lptxStock comparison

Financial Survey: Leap Therapeutics (NASDAQ:LPTX) & Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) and Leap Therapeutics (NASDAQ:LPTX – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability. Institutional & Insider Ownership 96.7% of Dyne Therapeutics […]

United statesNew zealandUnited kingdomDyne therapeutics incHealthcare pharmaceuticals incLeap therapeutics incBeigene ltdDyne therapeuticsGet free reportLeap therapeuticsGiven leap therapeuticLeap therapeuticHealthcare pharmaceuticalsDyne therapeutics dailyNasdaq dynStock comparison